The Current Status of COVID-19 Vaccines

Overview

Journal Front Genome Ed

Date 2021 Oct 29

PMID 34713220

Citations 16

Authors

Kenneth Lundstrom

Affiliations

Soon will be listed here.

Abstract

The current COVID-19 pandemic has substantially accelerated the demands for efficient vaccines. A wide spectrum of approaches includes live attenuated and inactivated viruses, protein subunits and peptides, viral vector-based delivery, DNA plasmids, and synthetic mRNA. Preclinical studies have demonstrated robust immune responses, reduced viral loads and protection against challenges with SARS-CoV-2 in rodents and primates. Vaccine candidates based on all delivery systems mentioned above have been subjected to clinical trials in healthy volunteers. Phase I clinical trials have demonstrated in preliminary findings good safety and tolerability. Evaluation of immune responses in a small number of individuals has demonstrated similar or superior levels of neutralizing antibodies in comparison to immunogenicity detected in COVID-19 patients. Both adenovirus- and mRNA-based vaccines have entered phase II and study protocols for phase III trials with 30,000 participants have been finalized.

Citing Articles

An update on vaccine status and the role of nanomedicine against SARS-CoV-2: A narrative review.

Tajnur R, Rezwan R, Aziz A, Islam M Health Sci Rep. 2023; 6(7):e1377.

PMID: 37404449 PMC: 10315735. DOI: 10.1002/hsr2.1377.

Nano-based techniques: A revolutionary approach to prevent covid-19 and enhancing human awareness.

Annamalai A, Karuppaiya V, Ezhumalai D, Cheruparambath P, Balakrishnan K, Venkatesan A J Drug Deliv Sci Technol. 2023; 86:104567.

PMID: 37313114 PMC: 10183109. DOI: 10.1016/j.jddst.2023.104567.

spores displaying RBD domain of SARS-CoV-2 spike protein.

Vetrakova A, Chovanova R, Rechtorikova R, Krajcikova D, Barak I Comput Struct Biotechnol J. 2023; 21:1550-1556.

PMID: 36778063 PMC: 9904849. DOI: 10.1016/j.csbj.2023.02.007.

COVID-19 signalome: Potential therapeutic interventions.

Lundstrom K, Hromic-Jahjefendic A, Bilajac E, Aljabali A, Baralic K, Sabri N Cell Signal. 2022; 103:110559.

PMID: 36521656 PMC: 9744501. DOI: 10.1016/j.cellsig.2022.110559.

Charge-Conversion Strategies for Nucleic Acid Delivery.

Dutta K, Das R, Medeiros J, Kanjilal P, Thayumanavan S Adv Funct Mater. 2022; 31(24).

PMID: 35832306 PMC: 9275120. DOI: 10.1002/adfm.202011103.

References

Jazayeri S, Poh C . Recent advances in delivery of veterinary DNA vaccines against avian pathogens. Vet Res. 2019; 50(1):78. PMC: 6785882. DOI: 10.1186/s13567-019-0698-z. View

Hooper J, Moon J, Paolino K, Newcomer R, McLain D, Josleyn M . A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for haemorrhagic fever with renal syndrome delivered by intramuscular electroporation. Clin Microbiol Infect. 2014; 20 Suppl 5:110-7. DOI: 10.1111/1469-0691.12553. View

Stachyra A, Redkiewicz P, Kosson P, Protasiuk A, Gora-Sochacka A, Kudla G . Codon optimization of antigen coding sequences improves the immune potential of DNA vaccines against avian influenza virus H5N1 in mice and chickens. Virol J. 2016; 13(1):143. PMC: 5000471. DOI: 10.1186/s12985-016-0599-y. View

Stefano M, Kream R, Stefano G . A Novel Vaccine Employing Non-Replicating Rabies Virus Expressing Chimeric SARS-CoV-2 Spike Protein Domains: Functional Inhibition of Viral/Nicotinic Acetylcholine Receptor Complexes. Med Sci Monit. 2020; 26:e926016. PMC: 7278327. DOI: 10.12659/MSM.926016. View

Zhou Z, Post P, Chubet R, Holtz K, McPherson C, Petric M . A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine. 2006; 24(17):3624-31. PMC: 7115485. DOI: 10.1016/j.vaccine.2006.01.059. View

Tlaxca J, Ellis S, Remmele Jr R . Live attenuated and inactivated viral vaccine formulation and nasal delivery: potential and challenges. Adv Drug Deliv Rev. 2014; 93:56-78. DOI: 10.1016/j.addr.2014.10.002. View

Kariko K, Buckstein M, Ni H, Weissman D . Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005; 23(2):165-75. DOI: 10.1016/j.immuni.2005.06.008. View

Broekhuijsen M, Blom T, van Rijn J, Pouwels P, Klasen E, Fasbender M . Synthesis of fusion proteins with multiple copies of an antigenic determinant of foot-and-mouth disease virus. Gene. 1986; 49(2):189-97. DOI: 10.1016/0378-1119(86)90279-9. View

Hoerr I, Obst R, Rammensee H, Jung G . In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol. 1999; 30(1):1-7. DOI: 10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-#. View

10.

Lundstrom K, Boulikas T . Viral and non-viral vectors in gene therapy: technology development and clinical trials. Technol Cancer Res Treat. 2003; 2(5):471-86. DOI: 10.1177/153303460300200513. View

11.

Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z . Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA. 2020; 324(10):951-960. PMC: 7426884. DOI: 10.1001/jama.2020.15543. View

12.

Kariko K, Muramatsu H, Welsh F, Ludwig J, Kato H, Akira S . Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008; 16(11):1833-40. PMC: 2775451. DOI: 10.1038/mt.2008.200. View

13.

Kim E, Erdos G, Huang S, Kenniston T, Balmert S, Donahue Carey C . Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development. EBioMedicine. 2020; 55:102743. PMC: 7128973. DOI: 10.1016/j.ebiom.2020.102743. View

14.

van Doremalen N, Miazgowicz K, Milne-Price S, Bushmaker T, Robertson S, Scott D . Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4. J Virol. 2014; 88(16):9220-32. PMC: 4136254. DOI: 10.1128/JVI.00676-14. View

15.

Harbury P, Kim P, Alber T . Crystal structure of an isoleucine-zipper trimer. Nature. 1994; 371(6492):80-3. DOI: 10.1038/371080a0. View

16.

Barrett P, Terpening S, Snow D, Cobb R, Kistner O . Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases. Expert Rev Vaccines. 2017; 16(9):883-894. DOI: 10.1080/14760584.2017.1357471. View

17.

Folegatti P, Ewer K, Aley P, Angus B, Becker S, Belij-Rammerstorfer S . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467-478. PMC: 7445431. DOI: 10.1016/S0140-6736(20)31604-4. View

18.

Morris A, Remmele Jr R, Klinke R, Macduff B, Fanslow W, Armitage R . Incorporation of an isoleucine zipper motif enhances the biological activity of soluble CD40L (CD154). J Biol Chem. 1998; 274(1):418-23. DOI: 10.1074/jbc.274.1.418. View

19.

McBurney S, Sunshine J, Gabriel S, Huynh J, Sutton W, Fuller D . Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates. Vaccine. 2016; 34(30):3500-7. PMC: 4959041. DOI: 10.1016/j.vaccine.2016.03.108. View

20.

Grantham R, Gautier C, Gouy M, Mercier R, Pave A . Codon catalog usage and the genome hypothesis. Nucleic Acids Res. 1980; 8(1):r49-r62. PMC: 327256. DOI: 10.1093/nar/8.1.197-c. View